Furthermore, the twice-daily radiation cohort demonstrated relatively superior QOL outcomes over time compared to the once-daily radiation group. Multivariable analyses adjusting for confounders corroborated these observations, lending credence to the hypothesis that twice-daily treatment schedules might confer qualitative advantages without compromising efficacy. Subject of Research: Limited-stage small cell lung cancer treatment; integration of immunotherapy with chemoradiation; patient-reported outcomes and quality of life analysis. Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC). Keywords: Small cell lung cancer, limited-stage, chemoradiation, atezolizumab, immunotherapy, patient-reported outcomes, quality of life, thoracic radiotherapy, twice-daily radiation, concurrent therapy, clinical trial, NRG Oncology